Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Ovarian Neoplasms 3Multiple Myeloma 3Lymphoma 3Urinary Bladder Neoplasms 2Lung Neoplasms 2Glioblastoma 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Somatostatinoma 1Sarcoma, Synovial 1Recurrent Lung Squamous Cell Carcinoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neurofibrosarcoma 1Neoplasm Metastasis 1Meningeal Neoplasms 1Melanoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hematologic Neoplasms 1Gliosarcoma 1Glioma 1Fibrolamellar hepatocellular carcinoma 1

Interventions

Cyclophosphamide 42Cytarabine 33Methotrexate 31Vincristine 27Filgrastim 26Etoposide 24Radiotherapy 19Peripheral Blood Stem Cell Transplantation 18Dexamethasone 18fludarabine phosphate 16Leucovorin 16Mercaptopurine 15Asparaginase 15Daunorubicin 14Prednisone 13merphos 12Doxorubicin 12Cyclosporine 11pegaspargase 10Vorinostat 10Rituximab 10Busulfan 10tanespimycin 9Ifosfamide 9Bortezomib 9Methylprednisolone 8Hydrocortisone 8Calcium Dobesilate 8fludarabine 7Tacrolimus 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Precursor Cell Lymphoblastic Leukemia-Lymphoma × sapanisertib × Clear all
NCT02484430 2025-03-03

Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 2 Completed
16 enrolled 8 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡